Olmesartan can inhibit the release of HMGB1 under stress significantly, thus inhibiting the excessive immune response and long-term inflammation, which promotes the development of CKD and ultimately leads to renal fibrosis. The gene discussed is HMGB1; the disease is chronic kidney disease.